Myelodysplastic/myeloproliferative neoplasm
Therapeutic area
Hematology
Rare disease
No
- Definition
- A category of clonal hematopoietic disorders that have both myelodysplastic and myeloproliferative features at the time of initial presentation.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Myelodysplastic/myeloproliferative neoplasm
- Therapeutic area
- Hematology
- myelodysplastic/myeloproliferative neoplasm
- MDS-MPD
- MDS/MPD
- myelodysplastic myeloproliferative disease
- myelodysplastic/myeloproliferative disease
- myelodysplastic/myeloproliferative diseases
- myelodysplastic/myeloproliferative disorder
- myelodysplastic/myeloproliferative disorders
- myeloproliferative/myelodysplastic disorders
- myeloproliferative/myelodysplastic syndromes
- MDS/MPN
- MPD-MDS
- MPD/MDS
- myelodysplastic/myeloproliferative neoplasm
- myelodysplastic/myeloproliferative neoplasms
- Severity
- Severe
- Hematology
- Immunology
- Oncology
- Rheumatology
- MONDO ID
- MONDO:0006311
- Parent condition
- MONDO:0020076
Related records
Broader conditions (27)
- Bone cancer
- Bone disorder
- Bone marrow cancer
- Bone marrow disorder
- Bone marrow neoplasm
- Bone neoplasm
- Cancer
- Cancer or benign tumor
- Connective tissue disorder
- Connective tissue neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
- Human disease
- Immune system cancer
- Immune system disorder
- Musculoskeletal system cancer
Narrower conditions (3)
- Atypical chronic myeloid leukemia, BCR-ABL1 negative
- Chronic myelomonocytic leukemia
- Juvenile myelomonocytic leukemia
Trials (709)
- (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
- 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II
- 3-AP and Cytarabine in Treating Patients With Hematologic Cancer
- 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
- 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
- 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
- A Case Control Study of the Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Diseases.
- A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors
- A New Blood Score for Myelofibrosis Staging
- A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemokine Receptor 2 Detection. From Flow Cytometry to the Development of Targeted Positron Emission Tomography Molecular Imaging. Pre-clinical Studies and First In-human Proof of Concept
- A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
- A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
- A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
- A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving
- A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
- A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
- A Phase I Trial of ZIO-101 in Hematologic Cancers
Drugs in development (2)
- Azacitidine Phase 2
- Ruxolitinib Phase 2
Other linked drugs (1)
- Imatinib